<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Braz J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Int Braz J Urol</journal-id><journal-id journal-id-type="publisher-id">ibju</journal-id><journal-title-group><journal-title>International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology</journal-title></journal-title-group><issn pub-type="ppub">1677-5538</issn><issn pub-type="epub">1677-6119</issn><publisher><publisher-name>Sociedade Brasileira de Urologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26742969</article-id><article-id pub-id-type="pmc">4756937</article-id><article-id pub-id-type="publisher-id">S1677-5538.IBJU.2014.0585</article-id><article-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2014.0585</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of mitochondrial potassium channel on the renal protection mediated by sodium thiosulfate against ethylene glycol induced nephrolithiasis in rat model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baldev</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sriram</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Prabu</surname><given-names>P.C.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gino</surname><given-names>A. Kurian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1"><label>1</label>School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India</aff><aff id="aff2"><label>2</label>Vascular Biology Lab, SASTRA University, Thanjavur, Tamil Nadu, India</aff><aff id="aff3"><label>3</label>Central Animal Facility, SASTRA University, Thanjavur, Tamil Nadu, India</aff></contrib-group><author-notes><corresp id="c1"><bold>Correspondence address:</bold> Gino A. Kurian, MD Vascular Biology Lab School of Chemical and Biotechnology SASTRA University Thanjavur, 613401, Tamilnadu, India E-mail: <email>ginokurian@hotmail.com</email></corresp><fn fn-type="conflict"><p>
<bold>CONFLICT OF INTEREST</bold>
</p><p>None declared</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2015</year></pub-date><volume>41</volume><issue>6</issue><fpage>1116</fpage><lpage>1125</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>ABSTRACT</title><sec><title>Purpose:</title><p>Sodium thiosulfate (STS) is clinically reported to be a promising drug in preventing nephrolithiasis. However, its mechanism of action remains unclear. In the present study, we investigated the role of mitochondrial KATP channel in the renal protection mediated by STS.</p></sec><sec><title>Materials and Methods:</title><p>Nephrolithiasis was induced in Wistar rats by administrating 0.4% ethylene glycol (EG) along with 1% ammonium chloride for one week in drinking water followed by only 0.75% EG for two weeks. Treatment groups received STS, mitochondrial KATP channel opener and closer exclusively or in combination with STS for two weeks.</p></sec><sec><title>Results:</title><p>Animals treated with STS showed normal renal tissue architecture, supported by near normal serum creatinine, urea and ALP activity. Diazoxide (mitochondria KATP channel opening) treatment to the animal also showed normal renal tissue histology and improved serum chemistry. However, an opposite result was shown by glibenclamide (mitochondria KATP channel closer) treated rats. STS administered along with diazoxide negated the renal protection rendered by diazoxide alone, while it imparted protection to the glibenclamide treated rats, formulating a mitochondria modulated STS action.</p></sec><sec><title>Conclusion:</title><p>The present study confirmed that STS render renal protection not only through chelation and antioxidant effect but also by modulating the mitochondrial KATP channel for preventing urolithiasis.</p></sec></abstract><kwd-group><title>Key words:</title><kwd>Diazoxide</kwd><kwd>glibenclamide receptor [Supplementary Concept]</kwd><kwd>Kidney Calculi</kwd><kwd>Calcium Oxalate</kwd><kwd>Pathology</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="30"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Nephrolithiasis is a complex disease of kidney where crystals or foreign bodies can act as nidi, upon which ions from the supersaturated urine form microscopic crystalline structures (<xref rid="B1" ref-type="bibr">1</xref>). The formation of these crystals in the tubular fluid, followed by crystal retention and accumulation in the kidney are the pre-requisite for the development of renal stone. Free particle model, fixed particle model and Randall's plaque hypothesis are some well-established hypothesis for stone formation and growth (<xref rid="B2" ref-type="bibr">2</xref>). However, molecular understanding of all these theories underlines the importance of oxidative stress in the renal stone formation.</p><p>Thiosulfate, an endogenous molecule derived from the metabolism of H<sub>2</sub>S, is reported to have antioxidant and chelation property (<xref rid="B3" ref-type="bibr">3</xref>). Sodium thiosulfate, FDA approved drug is used to lessen the side effects of cisplatin (<xref rid="B4" ref-type="bibr">4</xref>) and widely used in the emergency treatment of cyanide poisoning (<xref rid="B5" ref-type="bibr">5</xref>). Due to the availability of the sulfur group for the donations and free radical scavenging potential, STS can essentially act as an anti-urolithiatic agent (<xref rid="B6" ref-type="bibr">6</xref>). Few studies by Asplin and his co-workers and Yatzidis showed that thiosulfate can prevent calcium phosphate nephrolithiasis. However, LaGrange et al., 2009 reported negative results for thiosulfate in the prevention of calcium stone disease (<xref rid="B7" ref-type="bibr">7</xref>). In fact, in both studies, the mechanism by which STS affects calcium deposition was not clearly mentioned.</p><p>Potassium channels in nephrons have varied functions ranging from maintaining ionic equilibrium to regulating the volume during hypotonic stress environments. Their activation depends on location across the nephrons, as they can be activated either by altering pH, calcium, sodium, chloride or ATP levels. Thus, effects of K<sup>+</sup> channels are very complex to study (<xref rid="B8" ref-type="bibr">8</xref>). The present study was designed to understand the specific role of ATP sensitive potassium channel using diazoxide (channel opener) and glibenclamide (channel closer) in sodium thiosulfate mediated renal protection from ethylene glycol induced nephrolithiasis in a rat model. The calcium chelating potential of STS was evaluated in vitro using gel diffusion method.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Chemicals</title><p>Diazoxide was purchased from Sigma-Aldrich. All other commercial reagents used were of analytical grade.</p></sec><sec><title>Animals</title><p>All animal experiments were conducted in accordance with the CPCSEA (Committee for the purpose of conduct and supervision of experiments on animals) guidelines, approved by the institutional animal ethical committee (IAEC No. 214/SASTRA/IAEC), Central Animal Facility, SASTRA University. To demonstrate the anti-urolithiasis property and mechanism of action of sodium thiosulfate we used male albino Wistar rats aged 7 to 8 weeks (180-200g). Animals were kept in polycarbonate cages at a controlled temperature of 25&#x000b1;3&#x000b0;C and 60&#x000b1;10% relative humidity with a 12 h each of dark and light cycle. Rats were acclimatized for one week with standard laboratory diet and tap drinking water before the start of experiment.</p></sec><sec><title>Study design</title><p>Forty two male Wistar rats were assigned randomly into seven equal groups. All the doses were selected based on previous studies (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>).</p><list list-type="simple"><list-item><p>Group-1 (Normal control): received water ad libitum for 21 days.</p></list-item><list-item><p>Group-2 (Induction control): received 0.4% ethylene glycol (EG) along with 1% ammonium chloride for one week followed by only 0.75% EG in drinking water for two subsequent weeks.</p></list-item><list-item><p>Groups-3 to 7 received the same treatment as group 2 along with the following drug treatments:</p></list-item><list-item><p>Group-3 (STS): received sodium thiosulfate (400mg/Kg b.wt.) intraperitoneally for 21 days.</p></list-item><list-item><p>Group-4 (Diazoxide): received diazoxide (mito K<sub>ATP</sub> channel opener; 5mg/Kg b.wt.) intraperitoneally for 21 days.</p></list-item><list-item><p>Group-5 (Glibenclamide): received glibenclamide (mito K<sub>ATP</sub> channel closer; 10mg/ Kg b.wt.) intraperitoneally for 21 days</p></list-item><list-item><p>Group-6 (STS+Diazoxide): received diazoxide 30min. before administration of STS for 21 days.</p></list-item><list-item><p>Group-7 (STS+Glibenclamide): received glibenclamide 30min. before administration of STS for 21 days.</p></list-item></list></sec><sec><title>Biochemical Parameters</title><p>Urine samples from all groups were collected using metabolic cages for 24h and analyzed in triplicates for the levels of urea, creatinine and calcium using respective diagnostic kits from Agappe diagnostics Ltd (India). Whole blood was collected from the retro-orbital sinus on the day of necropsy, centrifuged at 10.000&#x000d7;g for 10 min. and serum chemistry analysis was performed in triplicates for calcium, creatinine, urea, ALP using the respective diagnostic kits purchased from Agappe diagnostics Ltd. &#x00026; Span diagnostics Ltd. (India).</p></sec><sec><title>Antioxidant assays</title><p>After necropsy left kidney was cut into four equal sections. Each section was weighed separately, crushed and homogenized in 3mL ice cold Tris buffer (pH=7.4) for performing various assays. Total protein content was measured by Lowry et al., (1956) (<xref rid="B10" ref-type="bibr">10</xref>) and used for further calculation. The remaining sample was used for the estimation of various antioxidant levels in kidney homogenate such as TBARS, SOD, GPX and catalase by previously described standard methods (<xref rid="B11" ref-type="bibr">11</xref>) while the level of ALP was measured using commercial kit.</p></sec><sec><title>Histopathology</title><p>After 21 days of treatment, rats were euthanized by carbon dioxide inhalation followed by cervical dislocation. Immediate laparotomy was performed to collect both the kidneys. Isolated kidneys were cleaned off the extraneous tissue, weighed and rinsed with ice-cold normal saline. A section from both kidneys was fixed with 10% v/v neutral formalin and processed through graded alcohol series and xylene, embedded in paraffin, sectioned at 5&#x003bc;m, and stained with hematoxylin and eosin for histopathological examination under a light microscope. Three kidney tissues per group were analyzed for nephropathy, obstruction and stone deposition.</p></sec><sec><title>In vitro gel diffusion model</title><p>To find the inhibitory effect of STS on calcium oxalate stone formation the gel diffusion assay was performed according to Li et al. with minor modifications (<xref rid="B12" ref-type="bibr">12</xref>). A microscope slide was uniformly coated with 3mL of 1% agar. After the agar solidified, two pairs of equidistant wells were made perpendicularly. Sodium oxalate and calcium chloride each 20&#x003bc;l was placed in vertical wells. The horizontal wells were filled either with 20&#x003bc;l distilled water as standard or 20&#x003bc;l of STS at varying concentrations. Then the slide was left in a moist chamber for 24h at room temperature. The calcium and oxalate ions diffuse through the gel and form crystals of calcium oxalate, visible as a cloudy streak in the center. The intensity of crystal formation and size of the crystals was dependent on the molarity of the crystal forming solutions employed. Depending on concentration, the inhibitory substances would modify the density and width of the crystal streak. This was carried out in triplicates with different concentrations (200mM, 100mM, 50mM, and 25mM) of STS. The slides were photographed using Gel Documentation System &#x02018;BioRad Chemidoc XRS&#x02019;. The images were analyzed using Image J software and densitometry plots were obtained. Relative density of the sample with respect to the control was obtained, and the percentage inhibition was calculated by the following formula: inhibition=1-(relative density of the sample/relative density of the control)*100.</p></sec></sec><sec><title>Statistical Analysis</title><p>Data was expressed as mean&#x000b1;SD. The comparison between groups, at various time points during the experiment was conducted using ANOVA followed by multiple comparison tests, particularly Dunnett's test using GraphPad Prism software version 5.0.</p></sec><sec sec-type="results"><title>RESULTS</title><p>Preliminary observations of the rats indicate that ethylene glycol consumption reduced the body weight while the urine output was elevated at the end of 21 days.</p><sec><title/><sec><title>Urine and Serum chemistry</title><p>
<xref ref-type="table" rid="t1">Table-1</xref> shows the levels of urea, creatinine and calcium in the urine, and their corresponding serum concentration is depicted in <xref ref-type="table" rid="t2">Table-2</xref>. Induction group rats showed a significant decrease in the concentration of urea, creatinine in urine, while its serum concentration was significantly higher as compared to normal control rats. Administration of rats with STS, diazoxide, glibenclamide+STS exhibits near normal levels of urea, creatinine and calcium in both urine and serum as compared to normal control rats.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Urine Chemistry.</title></caption><table frame="hsides" rules="groups"><colgroup width="12%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">Normal control</th><th align="center" rowspan="1" colspan="1">Induction control</th><th style="border-bottom: thin solid; border-color: #000000" align="center" colspan="5" rowspan="1">Treatment groups</th></tr><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">STS alone</th><th align="center" rowspan="1" colspan="1">Diazoxide alone</th><th align="center" rowspan="1" colspan="1">Glibenclamide alone</th><th align="center" rowspan="1" colspan="1">Diazoxide+STS</th><th align="center" rowspan="1" colspan="1">Glibenclamide+STS</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" rowspan="1" colspan="1">Urea (mg/mL)</td><td align="center" rowspan="1" colspan="1">11.12&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">6.06 &#x000b1;1.2*</td><td align="center" rowspan="1" colspan="1">9.07&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">10.77&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">7.33&#x000b1;0.8*</td><td align="center" rowspan="1" colspan="1">8.92&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">10.29&#x000b1;1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x000b5;m/L)</td><td align="center" rowspan="1" colspan="1">12.13&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">6.26&#x000b1;1.5*</td><td align="center" rowspan="1" colspan="1">9.42&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">8.99&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">3.94&#x000b1;0.2*</td><td align="center" rowspan="1" colspan="1">6.93&#x000b1;1.8*</td><td align="center" rowspan="1" colspan="1">7.24&#x000b1;1.5*</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium (mg/24hr)</td><td align="center" rowspan="1" colspan="1">0.95&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">2.44&#x000b1;0.2*</td><td align="center" rowspan="1" colspan="1">1.10&#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">0.69&#x000b1;0.1*</td><td align="center" rowspan="1" colspan="1">1.23&#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.28&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">0.60&#x000b1;0.1*</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>
<bold>Group-1</bold> = served as normal control; <bold>Group-2</bold> = as a stone induction control; <bold>Group-3</bold> = was given STS; <bold>Group-4 and Group-5</bold> = were administered diazoxide and glibenclamide respectively and <bold>Groups 6 and 7</bold> = were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean&#x000b1;SD (*) p&#x0003c;0.05, statistically different from normal controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>serum Chemistry.</title></caption><table frame="hsides" rules="groups"><colgroup width="12%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">Normal control</th><th align="center" rowspan="1" colspan="1">Induction control</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Treatment groups</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">STS alone</th><th align="center" rowspan="1" colspan="1">Diazoxide alone</th><th align="center" rowspan="1" colspan="1">Glibenclamide alone</th><th align="center" rowspan="1" colspan="1">Diazoxide +STS</th><th align="center" rowspan="1" colspan="1">Glibenclamide +STS</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">16.50&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">41.94&#x000b1;1.1*</td><td align="center" rowspan="1" colspan="1">18.76&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">19.55&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">29.93&#x000b1;1.2*</td><td align="center" rowspan="1" colspan="1">16.42&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">13.74&#x000b1;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/ dL)</td><td align="center" rowspan="1" colspan="1">0.35&#x000b1;0.02</td><td align="center" rowspan="1" colspan="1">1.03&#x000b1;0.07*</td><td align="center" rowspan="1" colspan="1">0.38&#x000b1;0.02</td><td align="center" rowspan="1" colspan="1">0.35&#x000b1;0.06</td><td align="center" rowspan="1" colspan="1">0.58&#x000b1;0.02*</td><td align="center" rowspan="1" colspan="1">0.38&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.35&#x000b1;0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">ALP (U/L)</td><td align="center" rowspan="1" colspan="1">57.03&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">115.96&#x000b1;2.9*</td><td align="center" rowspan="1" colspan="1">49.25&#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">50.73&#x000b1;3.2</td><td align="center" rowspan="1" colspan="1">76.18&#x000b1;2.4*</td><td align="center" rowspan="1" colspan="1">70.14&#x000b1;4.2*</td><td align="center" rowspan="1" colspan="1">41.39&#x000b1;2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium (mg/dL)</td><td align="center" rowspan="1" colspan="1">6.21&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">5.14&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">4.46&#x000b1;0.7*</td><td align="center" rowspan="1" colspan="1">3.34&#x000b1;0.7*</td><td align="center" rowspan="1" colspan="1">1.57&#x000b1;0.2*</td><td align="center" rowspan="1" colspan="1">4.31&#x000b1;0.7*</td><td align="center" rowspan="1" colspan="1">4.10&#x000b1;0.9*</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>
<bold>Group-1</bold> = served as normal control; <bold>Group-2</bold> = as a stone induction control; <bold>Group-3</bold> = was given STS; <bold>Group-4 and Group-5</bold> = were administered diazoxide and glibenclamide respectively and <bold>Groups 6 and 7</bold> were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean&#x000b1;SD (*) p&#x0003c;0.05, statistically different from normal controls.</p></fn></table-wrap-foot></table-wrap><p>According to Leibovitch, (<xref rid="B13" ref-type="bibr">13</xref>) elevated serum ALP is an indicator of kidney dysfunction, and its levels in the blood can be used as an index to assess the effectiveness of the treatment. Administration of STS, diazoxide and glibenclamide+STS to rats reduced the significant elevation of serum ALP activity (<xref ref-type="table" rid="t2">Table-2</xref>) shown in induction control groups as compared to normal control rats.</p></sec><sec><title>Antioxidant status</title><p>Ethylene glycol administration to the rat was reported to alter the oxidant and antioxidant balance in the kidney and thereby induces nephrolithiasis in two phases. Initially, it causes the production of free radicals and in the later stage, it initiates infiltration of leukocytes (<xref rid="B14" ref-type="bibr">14</xref>). Ethylene glycol treatment significantly (P&#x0003c;0.001) increased the TBARS levels, decreased superoxide dismutase and glutathione peroxidase in the induction control group compared to normal rats. The treatment with STS (400mg/kg) to the rats significantly (P&#x0003c;0.05) reduced the TBARS levels and improved the antioxidant enzymes activities compared to group 2 (<xref ref-type="table" rid="t3">Table-3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Lipid peroxidation and antioxidant levels.</title></caption><table frame="hsides" rules="groups"><colgroup width="12%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000"><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1">Parameters</th><th align="center" rowspan="1" colspan="1">Normal control</th><th align="center" rowspan="1" colspan="1">Induction control</th><th style="border-bottom: thin solid; border-color: #000000" align="center" colspan="5" rowspan="1">Treatment groups</th></tr><tr style="background-color: #E7E7E8"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">STS alone</th><th align="center" rowspan="1" colspan="1">Diazoxide alone</th><th align="center" rowspan="1" colspan="1">Glibenclamide alone</th><th align="center" rowspan="1" colspan="1">Diazoxide +STS</th><th align="center" rowspan="1" colspan="1">Glibenclamide +STS</th></tr></thead><tbody style="border-bottom: thin solid; border-color: #000000"><tr><td align="left" rowspan="1" colspan="1">TBARS (mM/100g tissue)</td><td align="center" rowspan="1" colspan="1">1.78&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">4.21&#x000b1;0.5*</td><td align="center" rowspan="1" colspan="1">2.10&#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">0.84&#x000b1;0.09*</td><td align="center" rowspan="1" colspan="1">0.74&#x000b1;0.05*</td><td align="center" rowspan="1" colspan="1">0.71&#x000b1;0.03*</td><td align="center" rowspan="1" colspan="1">0.72&#x000b1;0.08*</td></tr><tr><td align="left" rowspan="1" colspan="1">Superoxide Dismutase (Units/mg protein)</td><td align="center" rowspan="1" colspan="1">34.7&#x000b1;4.5</td><td align="center" rowspan="1" colspan="1">17.64&#x000b1;1.2*</td><td align="center" rowspan="1" colspan="1">31.24&#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">26.47&#x000b1;1.2*</td><td align="center" rowspan="1" colspan="1">25.63&#x000b1;1.3*</td><td align="center" rowspan="1" colspan="1">29.91&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">32.30&#x000b1;2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Glutathione peroxidase (&#x000b5;g of GSH utilized/min/ mg protein)</td><td align="center" rowspan="1" colspan="1">22&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">12.13&#x000b1;1.1*</td><td align="center" rowspan="1" colspan="1">19.14&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">15.54&#x000b1;1.3*</td><td align="center" rowspan="1" colspan="1">16.66&#x000b1;1.5*</td><td align="center" rowspan="1" colspan="1">19.82&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">19.57&#x000b1;1.4</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>
<bold>Group-1</bold> = served as normal control; <bold>Group-2</bold> = as a stone induction control; <bold>Group-3</bold> = was given STS; <bold>Group-4 and Group-5</bold> = were administered diazoxide and glibenclamide respectively and <bold>Groups 6 and 7</bold> = were pretreated with diazoxide and glibenclamide respectively half an hour before administration of STS. Data of all results are presented as mean&#x000b1;SD (*) p&#x0003c;0.05, statistically different from normal controls.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Histopathology</title><p>Histopathological analysis of renal tissues in the control group showed no calcium oxalate deposits or other abnormalities in different segments of the nephrons (<xref ref-type="fig" rid="f1">Figure-1</xref>A). But in the urolithiasis induction group, a substantial amount of calcium oxalate deposition was observed, and this was present in whole parts of three major areas of the kidney (<xref ref-type="fig" rid="f1">Figure-1</xref>B). Renal tubular dilations with tubular basophilic and epithelial damage were also observed on pathological examination. In sodium thiosulfate treated group the number of calcium oxalate deposits was significantly lower than that in the disease control group with only mild nephropathy in one of the animals in that group (<xref ref-type="fig" rid="f1">Figure-1</xref>C). Rats treated with diazoxide alone showed less obstructive damage (<xref ref-type="fig" rid="f1">Figure-1</xref>D) while glibenclamide treated rats showed severe damage and obstruction (<xref ref-type="fig" rid="f1">Figure-1</xref>E). Apparently more renal damage, inflammation and hemolysis were observed in rats co-administered with STS and diazoxide (<xref ref-type="fig" rid="f1">Figure-1</xref>F) while STS administration along with glibenclamide showed preserved renal tissue with mild obstruction (<xref ref-type="fig" rid="f1">Figure-1</xref>G).</p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Light microscopic architecture of kidney showing (A) Renal tissue of control (group 1) rats showing no sign of crystal deposition. (B) Renal tissue of urolithiatic rats (group 2) showing crystals deposition and severe obstructive nephropathy (C) Renal tissue of (group 3) STS treated rats showing mild crystal deposition with mild nephropathy. (D) Renal tissue of (group 4) diazoxide treated rats showing mild crystal deposition with moderate obstructive nephropathy (E) Renal tissue of (group 5) glibenclamide treated rats showing prominent crystal deposition with severe obstructive nephropathy (f) Renal tissue of (group 6) diazoxide +STS treated rats showing crystal deposition with severe obstructive nephropathy (g) Renal tissue of (group 7) glibenclamide + STS pretreated rats low crystal deposition with mild nephropathy (h) Crystal's deposition as observed under 40X zoom.</title></caption><graphic xlink:href="1677-5538-ibju-41-6-1116-gf01"/></fig></sec><sec><title>In vitro gel analysis to study chelation effect</title><p>In order to re-confirm the inhibitory effect of STS on calcium oxalate crystal, we performed an in-vitro analysis. The calcium oxalate crystals that have been produced in this study were similar to the crystals in the urine of patients with calcium oxalate crystals. The crystals were predominantly of monohydrate type, confirmed by FTIR. According to <xref ref-type="fig" rid="f2">Figure-2</xref>, STS showed a dose-dependent inhibition of calcium oxalate stone formation. Apparently, only 18% direct inhibition was shown with maximum STS concentration of 200mM, indicating an additional tissue based mechanism for its renal protective action.</p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Images of agar gel slides and graph representing the percentage inhibition produced by STS in calcium oxalate crystal formation represented as a streak.</title></caption><graphic xlink:href="1677-5538-ibju-41-6-1116-gf02"/></fig></sec></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Urinary lithiasis is a multifactorial urological disorder that generally occurs as a result of an imbalance between inhibitors and promoters for renal stone formation (<xref rid="B15" ref-type="bibr">15</xref>). The human kidney stones predominantly comprised of calcium oxalate, and few studies have examined the effect of the sodium thiosulfate on calcium oxalate crystallization (<xref rid="B16" ref-type="bibr">16</xref>) as well. However, the conclusions from those studies were not consistent as few studies claim the beneficial effect of STS and while others, its negative result (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). In the present study, we investigated the effect of sodium thiosulfate on renal stone formation in both in vivo and in vitro models and evaluated its mechanism of action. Our study results were in agreement with previous reports that suggested anti-urolithiatic property of STS but provides a new direction for its mode of action where STS may modulate mitochondrial K<sub>ATP</sub> channel in rendering renal protection.</p><p>Evidence in the literature showed that sodium thiosulfate reduces calcium phosphate stone formation in the genetic hypercalciuric rat (<xref rid="B6" ref-type="bibr">6</xref>). However, very little data on the use of sodium thiosulfate for calcium oxalate nephrolithiasis has been published. Adherence of calcium oxalate to renal tubules is associated with free radical mediated injury and the resultant oxidative stress due to hyperoxaluria, which favors crystal adherence (<xref rid="B17" ref-type="bibr">17</xref>). Administration of STS to rats for 21 days not only reduced the stress mediated by ethylene glycol, but also prevented the renal dysfunction measured by biochemical parameters like urea and creatinine in urine and serum. Elevated serum alkaline phosphatase activity is considered to be an indicator of renal damage (<xref rid="B18" ref-type="bibr">18</xref>). The increased serum ALP activity may be derived from the injury to the brush border membrane of the renal tubular cells (<xref rid="B19" ref-type="bibr">19</xref>). The near-normal activity of ALP in the present study was in agreement with the other group that showed a significant decline of ALP activity after STS administration in uremic rats (<xref rid="B20" ref-type="bibr">20</xref>). Further evidence for STS protection was confirmed through histological results where papillary crystalline deposits and calcium parenchyma deposits were absent. The direct interaction of STS on calcium oxalate formation was confirmed by using in vitro gel technique and found around 18% inhibition in calcium oxalate formation with 200mM STS, suggesting indirect action of STS in preventing renal stone formation.</p><p>A direct co-relation between renal mitochondrial dysfunction and ethylene glycol induced calcium oxalate formation was reported, where the exposure of the proximal tubule with calcium oxalate crystals resulted in rapid and progressive osmotic swelling and dissipation of transmembrane potential of mitochondria resulted in its damage (<xref rid="B21" ref-type="bibr">21</xref>). The peroxidation of protein had greater influence on the nucleation and aggregation property of calcium oxalate crystal growth and that predominantly occur in mitochondria (<xref rid="B22" ref-type="bibr">22</xref>). Mitochondrial permeability transition pore (mPTP) opening is a terminal event leading to mitochondrial dysfunction and cell death under conditions of oxidative stress. In fact, the vulnerability of the renal tissue towards oxidative stress depends on the functional cross talks between mPTP and mitochondrial K<sub>ATP</sub> channel (<xref rid="B23" ref-type="bibr">23</xref>). In the present study, we evaluated the specific role of mitochondrial potassium ATP channel in the sodium thiosulfate mediated renal protection.</p><p>Acccording to previous study results, it is believed that renal protection mediated by sodium thiosulfate is mainly attributed to its chelation and antioxidant potential (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B24" ref-type="bibr">24</xref>). However, thiosulfates are metabolized in mitochondria, and thus we anticipated a mitochondria based mechanism for its renal protection. In this connection, we used a mitochondrial potassium channel blocker glibenclamide (binds to sulphonylurea receptor subtypes of K<sub>ATP</sub> channel) and channel opener diazoxide (binds to ATP binding sites of sulphonylurea receptor subtypes of K<sub>ATP</sub> channel) to evaluate the renal status as supported by biochemical parameters and histopathology (<xref ref-type="fig" rid="f1">Figure-1</xref>, <xref ref-type="table" rid="t1">Tables 1</xref>&#x02013;<xref ref-type="table" rid="t3">3</xref>).</p><p>Glibenclamide showed a prominent renal injury as evidenced from altered serum and urine chemistry that was clearly demarcated in histopathology (<xref ref-type="fig" rid="f1">Figure-1</xref>E, <xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref>). Several lines of evidence showed that glibenclamide can depolarize mitochondrial membrane leading to calcium overload, one of the major factors responsible for free radical release and injury as evident from the lipid peroxidation and antioxidant marker enzyme levels (<xref ref-type="table" rid="t3">Table-3</xref>). On the other hand, ATP sensitive potassium channel opener, diazoxide treatment showed well-preserved architecture of the kidney (<xref ref-type="fig" rid="f1">Figure-1</xref>D). It prevented mitochondrial swelling and depolarization that may result in permeability pore transition and leads to tissue injury (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Diazoxide can also modulate the renin angiotensin system, that may play a significant role in developing renal tubule interstitial fibrosis (<xref rid="B27" ref-type="bibr">27</xref>) and resulting stone formation as reported with ethylene glycol induced renal injury. Although the mechanism by which the K<sub>ATP</sub> opener exert their renal protection have not been clarified yet, it is believed that the opening of K<sub>ATP</sub> channel preserves mitochondrial functional activities through mild uncoupling and depolarization (<xref rid="B28" ref-type="bibr">28</xref>). Thus diazoxide mediated protection is an impact on the mitochondria.</p><p>In order to confirm the STS mediated mitochondrial K<sub>ATP</sub> channel modulatory effect, we administered STS along with diazoxide (mitochondrial K<sub>ATP</sub> channel opener) and glibenclamide (mitochondrial K<sub>ATP</sub> channel blocker). We found interesting results, where the protective effect shown by diazoxide treatment alone was negated by STS supplementation. On the other hand, STS supplementation to glibenclamide group showed preserved renal tissue architecture. This inverse relationship of STS is an evidence for its interaction with mito K<sub>ATP</sub> Diazoxide binds to an ATP-sensitive K<sup>+</sup> transport pathway in kidney mitochondria that affects volume, respiration, and membrane potential and may have a role in the prevention of mitochondrial ATP hydrolysis. Opening of this channel leads to mild uncoupling, blocks calcium entry into mitochondria and leading to renal protection (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). As both diazoxide and STS (mediated through H2S formation) binds to KATP channel in different sites, when diazoxide and STS are given concomitantly, long term or excessive uncoupling may be expected causing ATP hydrolysis and mPTP opening without impairing electron transport, leading to apoptosis. On the other hand, glibenclamide binds to different sulfonylurea subunit blocking potassium entry, thereby exaggerating the ROS production and destabilizing the membrane potential leading to apoptosis (<xref rid="B28" ref-type="bibr">28</xref>). When STS is given with glibenclamide, we predict that, H<sub>2</sub>S released from STS may bind to Kir6. 1 subunit of mito K<sub>ATP</sub> channel, thereby reducing the binding efficiency of glibenclamide resulting its limited action of K<sub>ATP</sub> channel, allowing STS to mediated its renal protection.</p><p>The protective mechanism induced by the opening of mito K<sub>ATP</sub> is well-studied in cardiovascular diseases. Analogous to the heart system, renal protection by diazoxide may well be claimed due to i) Changes in the mitochondrial Ca<sup>2+</sup> levels ii) Mitochondrial matrix swelling and changes in ATP synthesis iii) Changes in the ROS levels. Sodium thiosulfate is a known calcium chelating agent with antioxidant properties (<xref rid="B30" ref-type="bibr">30</xref>) and can render electrons to complex IV upon its metabolism. Furthermore, several lines of the reports suggest that mitochondrial K<sub>ATP</sub> channel opening may inhibit mitochondrial permeability transition through inhibiting calcium overload and thereby preserve mitochondrial functions. A proven relationship between mitochondrial membrane potential, mitochondrial dependent apoptosis and calcium overload predicts the possibility of thiosulfate mediated calcium signaling mechanism through calcium/calmodulin-dependent protein kinase for its action, proposed for the future study.</p><p>The present study enhances the existing knowledge of STS mediated anti urolithiatic mechanism that emphasizes the calcium chelation and antioxidant property of STS alone. Based on our findings, we suggest that thiosulfate modulate the mitochondrial K<sub>ATP</sub> channel to render renal protection against stone formation.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Based on the results, we found that the administration of sodium thiosulfate effectively prevented the development of urolithiasis in rats, in agreement with the findings of Asplin &#x00026; Onyeka groups. Even though few mechanisms were proposed earlier for the anti-urolithiasis effect of sodium thiosulfate, no conclusive understanding was reached, and the present study confirm the specific role of ATP sensitive mitochondrial K<sub>ATP</sub> channel in STS mediated renal protective mechanism.</p></sec></body><back><glossary id="GL"><def-list><title>Abbreviations</title><def-item><term id="G1">STS =</term><def><p>Sodium thiosulfate</p></def></def-item><def-item><term id="G2">EG =</term><def><p>ethylene Glycol</p></def></def-item><def-item><term id="G3">K<sub>ATP</sub> =</term><def><p>Potassium ATP channel</p></def></def-item><def-item><term id="G4">mPTP =</term><def><p>mitochondrial permeability transition pore</p></def></def-item><def-item><term id="G5">ROS =</term><def><p>reactive oxygen species</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>KP</given-names></name><name><surname>Narula</surname><given-names>S</given-names></name><name><surname>Kakkar</surname><given-names>M</given-names></name><name><surname>Tandon</surname><given-names>C</given-names></name></person-group><article-title>Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators</article-title><source>Biomed Res Int</source><year>2013</year><volume>2013</volume><fpage>292953</fpage><lpage>292953</lpage><pub-id pub-id-type="pmid">24151593</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matlaga</surname><given-names>BR</given-names></name><name><surname>Coe</surname><given-names>FL</given-names></name><name><surname>Evan</surname><given-names>AP</given-names></name><name><surname>Lingeman</surname><given-names>JE</given-names></name></person-group><article-title>The role of Randall's plaques in the pathogenesis of calcium stones</article-title><source>J Urol</source><year>2007</year><volume>177</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17161996</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>KM</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name></person-group><article-title>Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches</article-title><source>Oxid Med Cell Longev</source><year>2010</year><volume>3</volume><fpage>109</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">20716935</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickey</surname><given-names>DT</given-names></name><name><surname>Wu</surname><given-names>YJ</given-names></name><name><surname>Muldoon</surname><given-names>LL</given-names></name><name><surname>Neuwelt</surname><given-names>EA</given-names></name></person-group><article-title>Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels</article-title><source>J Pharmacol Exp Ther</source><year>2005</year><volume>314</volume><fpage>1052</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">15951398</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamel</surname><given-names>J</given-names></name></person-group><article-title>A review of acute cyanide poisoning with a treatment update</article-title><source>Crit Care Nurse</source><year>2011</year><volume>31</volume><fpage>72</fpage><lpage>81</lpage><comment>quiz 82</comment><pub-id pub-id-type="pmid">21285466</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asplin</surname><given-names>JR</given-names></name><name><surname>Donahue</surname><given-names>SE</given-names></name><name><surname>Lindeman</surname><given-names>C</given-names></name><name><surname>Michalenka</surname><given-names>A</given-names></name><name><surname>Strutz</surname><given-names>KL</given-names></name><name><surname>Bushinsky</surname><given-names>DA</given-names></name></person-group><article-title>Thiosulfate reduces calcium phosphate nephrolithiasis</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><fpage>1246</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">19369406</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaGrange</surname><given-names>CA</given-names></name><name><surname>Lele</surname><given-names>SM</given-names></name><name><surname>Pais</surname><given-names>VM</given-names><suffix>Jr</suffix></name></person-group><article-title>The effect of sodium thiosulfate administration on nephrocalcinosis in a rat model</article-title><source>J Endourol</source><year>2009</year><volume>23</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">19193134</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhiya</surname><given-names>S</given-names></name><name><surname>Dkhar</surname><given-names>SA</given-names></name></person-group><article-title>Potassium channels in health, disease &#x00026; development of channel modulators</article-title><source>Indian J Med Res</source><year>2009</year><volume>129</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">19491413</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahgozar</surname><given-names>M</given-names></name><name><surname>Pazokitoroudi</surname><given-names>H</given-names></name><name><surname>Bakhtiarian</surname><given-names>A</given-names></name><name><surname>Djahanguiri</surname><given-names>B</given-names></name></person-group><article-title>Diazoxide, a K(ATP) opener, accelerates restitution of ethanol or indomethacin-induced gastric ulceration in rats independent of polyamines</article-title><source>J Gastroenterol Hepatol</source><year>2001</year><volume>16</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">11339420</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Rosebrough</surname><given-names>NJ</given-names></name><name><surname>Farr</surname><given-names>AL</given-names></name><name><surname>Randall</surname><given-names>RJ</given-names></name></person-group><article-title>Protein measurement with the Folin phenol reagent</article-title><source>J Biol Chem</source><year>1951</year><volume>193</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">14907713</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurian</surname><given-names>GA</given-names></name><name><surname>Paddikkala</surname><given-names>J</given-names></name></person-group><article-title>Administration of aqueous extract of Desmodium gangeticum (L) root protects rat heart against ischemic reperfusion injury induced oxidative stress</article-title><source>Indian J Exp Biol</source><year>2009</year><volume>47</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">19374168</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>SA</given-names></name><name><surname>See</surname><given-names>TL</given-names></name><name><surname>Khuay</surname><given-names>LY</given-names></name><name><surname>Osman</surname><given-names>K</given-names></name><name><surname>Abu Bakar</surname><given-names>MA</given-names></name></person-group><article-title>In vitro effects of plantago major extract on urolithiasis</article-title><source>Malays J Med Sci</source><year>2005</year><volume>12</volume><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">22605954</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibovitch</surname><given-names>I</given-names></name><name><surname>Ben-Chaim</surname><given-names>J</given-names></name><name><surname>Ramon</surname><given-names>J</given-names></name><name><surname>Goldwasser</surname><given-names>B</given-names></name></person-group><article-title>Increased serum alcaline phosphatase activity: a possible indicator of renal damage</article-title><source>J Clin Lab Anal</source><year>1991</year><volume>5</volume><fpage>406</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">1774605</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HS</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Ma</surname><given-names>MC</given-names></name></person-group><article-title>Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors</article-title><source>Kidney Int</source><year>2006</year><volume>70</volume><fpage>699</fpage><lpage>710</lpage><comment>Erratum in: Kidney Int. 2007;71:712</comment><pub-id pub-id-type="pmid">16807540</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worcester</surname><given-names>EM</given-names></name><name><surname>Coe</surname><given-names>FL</given-names></name></person-group><article-title>Clinical practice. Calcium kidney stones</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">20818905</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daudon</surname><given-names>M</given-names></name><name><surname>Knebelmann</surname><given-names>B</given-names></name></person-group><article-title>Calcium oxalate urolithiasis</article-title><source>Rev Prat</source><year>2011</year><volume>61</volume><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">21563420</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>C</given-names></name><name><surname>Koul</surname><given-names>H</given-names></name><name><surname>Hill</surname><given-names>WA</given-names></name><name><surname>Luber-Narod</surname><given-names>J</given-names></name><name><surname>Kennington</surname><given-names>L</given-names></name><name><surname>Honeyman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Oxalate toxicity in LLC-PK1 cells: role of free radicals</article-title><source>Kidney Int</source><year>1996</year><volume>49</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">8821825</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellwood</surname><given-names>JM</given-names></name><name><surname>Lovell</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>AE</given-names></name><name><surname>Tighe</surname><given-names>JR</given-names></name></person-group><article-title>Renal damage caused by gentamicin: a study of the effects on renal morphology and urinary enzyme excretion</article-title><source>J Pathol</source><year>1976</year><volume>118</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">1263024</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amador</surname><given-names>Ee</given-names></name><name><surname>Ddorfman</surname><given-names>LE</given-names></name><name><surname>Wacker</surname><given-names>WE</given-names></name></person-group><article-title>Urinary alkaline phosphatase and LDH activities in the differential diagnosis of renal disease</article-title><source>Ann Intern Med</source><year>1965</year><volume>62</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">14258348</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>WC</given-names></name><name><surname>Hardcastle</surname><given-names>KI</given-names></name></person-group><article-title>The chemistry of thiosulfate and vascular calcification</article-title><source>Nephrol Dial Transplant</source><year>2012</year><volume>27</volume><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">21737516</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMartin</surname><given-names>KE</given-names></name><name><surname>Wallace</surname><given-names>KB</given-names></name></person-group><article-title>Calcium oxalate monohydrate, a metabolite of ethylene glycol, is toxic for rat renal mitochondrial function</article-title><source>Toxicol Sci</source><year>2005</year><volume>84</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15601675</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindaraj</surname><given-names>A</given-names></name><name><surname>Selvam</surname><given-names>R</given-names></name></person-group><article-title>Increased calcium oxalate crystal nucleation and aggregation by peroxidized protein of human kidney stone matrix and renal cells</article-title><source>Urol Res</source><year>2001</year><volume>29</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11482446</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Kauffman</surname><given-names>J</given-names></name><name><surname>Akar</surname><given-names>FG</given-names></name></person-group><article-title>Functional crosstalk between the mitochondrial PTP and KATP channels determine arrhythmic vulnerability to oxidative stress</article-title><source>Front Physiol</source><year>2014</year><volume>5</volume><fpage>264</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">25076913</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Tyagi</surname><given-names>SC</given-names></name><name><surname>Kolb</surname><given-names>L</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><name><surname>Khanna</surname><given-names>R</given-names></name></person-group><article-title>Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxiscalcific uremic arteriolopathy: the emerging role of sodium thiosulfate</article-title><source>Cardiovasc Diabetol</source><year>2005</year><volume>4</volume><fpage>4</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15777477</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>JN</given-names></name><name><surname>Korge</surname><given-names>P</given-names></name><name><surname>Honda</surname><given-names>HM</given-names></name><name><surname>Ping</surname><given-names>P</given-names></name></person-group><article-title>Role of the mitochondrial permeability transition in myocardial disease</article-title><source>Circ Res</source><year>2003</year><volume>93</volume><fpage>292</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">12933700</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halestrap</surname><given-names>AP</given-names></name><name><surname>Clarke</surname><given-names>SJ</given-names></name><name><surname>Javadov</surname><given-names>SA</given-names></name></person-group><article-title>Mitochondrial permeability transition pore opening during myocardial reperfusion&#x02013;a target for cardioprotection</article-title><source>Cardiovasc Res</source><year>2004</year><volume>61</volume><fpage>372</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">14962470</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;ster</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>G</given-names></name></person-group><article-title>Renin-angiotensin-aldosterone system and progression of renal disease</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>2985</fpage><lpage>2991</lpage><pub-id pub-id-type="pmid">17035613</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancherini</surname><given-names>DV</given-names></name><name><surname>Trabuco</surname><given-names>LG</given-names></name><name><surname>Rebou&#x000e7;as</surname><given-names>NA</given-names></name><name><surname>Kowaltowski</surname><given-names>AJ</given-names></name></person-group><article-title>ATP-sensitive K+ channels in renal mitochondria</article-title><source>Am J Physiol Renal Physiol</source><year>2003</year><volume>285</volume><fpage>F1291</fpage><lpage>F1296</lpage><pub-id pub-id-type="pmid">12952853</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasinath</surname><given-names>BS</given-names></name></person-group><article-title>Hydrogen sulfide to the rescue in obstructive kidney injury</article-title><source>Kidney Int</source><year>2014</year><volume>85</volume><fpage>1255</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">24875544</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garlid</surname><given-names>KD</given-names></name><name><surname>Dos Santos</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>ZJ</given-names></name><name><surname>Costa</surname><given-names>AD</given-names></name><name><surname>Paucek</surname><given-names>P</given-names></name></person-group><article-title>Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection</article-title><source>Biochim Biophys Acta</source><year>2003</year><volume>1606</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">14507424</pub-id></element-citation></ref></ref-list></back></article>